香港科技探索(01137.HK):要約已截止
格隆匯8月12日丨香港科技探索(01137.HK)公吿,該等要約已於2025年8月12日下午四時正截止,且並無由要約人修訂或延長。
於2025年8月12日下午四時正,要約人已接獲:(i)合共1,865,248股要約股份的8份有效接納,佔本聯合公吿日期已發行股份總數約0.24%;及(ii)概無就期權要約接獲有效接納。
緊隨該等要約截止後及於本聯合公吿日期,待完成向要約人轉讓接獲有效接納的要約股份後,383,129,593股股份(佔全部已發行股份約48.41%)由公眾人士持有。因此,於本聯合公吿日期,公司繼續符合25%的最低公眾持股量規定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.